Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

."

Of the 15 evaluable patients who achieved stable disease or PRs, eight remain on study and are continuing to receive additional cycles of treatment. Of note, four of the patients with measurable tumor shrinkage, including the two patients with PRs, previously failed prior platinum-containing regimens and treatment with doxorubicin HCl liposome injection (Doxil(R)). Of the 2 patients with PRs, one has received eight cycles of treatment and continues on study. The other patient progressed within 60 days of initial response.

Sunesis plans to enroll approximately 55 patients in this clinical trial. Thirty-one patients have been enrolled to date, and Sunesis expects to complete enrollment and present additional data in 2008.

"We are pleased to report SNS-595's early, yet positive, demonstration of clinical activity. We have met the pre-specified criterion to advance this compound to the second stage of our Phase 2 clinical trial, by showing sufficient evidence of anti-tumor activity," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Additionally, the data suggests that SNS-595 may have potentially meaningful activity among platinum-resistant ovarian cancer patients who have also failed treatment with Doxil."

In parallel with the Phase 2 clinical trial, a non-clinical study was conducted to evaluate the activity of SNS-595 against 17 archived ovarian tumor biopsy specimens in the Extreme Drug Resistance (EDR(R)) cell proliferation assay. SNS-595 activity was compared to doxorubicin, etoposide and carboplatin -- agents used commonly in the treatment of ovarian cancer. Results from this study demonstrate that SNS-595 is a potent inhibitor of ovarian tumor cell growth, with activity comparing favorably to these agents. Further, none of the ovarian tumor samples showed any resistance to SNS-595.

These data were presented today during Poster Session A -- Clinical Trials at the AACR-NCI-EORT
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ... Report on China,s Ranibizumab Market, 2012-2019" report to ... approved by CFDA to treat wet age- related macular ... of Novartis, is available in the Chinese market. However, ... for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... MESA, Ariz., March 16, 2012 /PRNewswire/ -- On ... filed a collective action lawsuit against Sunovion Pharmaceuticals for failure ... are entitled under the Fair Labor Standards Act (FLSA). The Complaint ... District of Oregon on behalf of all Sunovion pharmaceutical reps ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation and autoimmune disorders, today provided an update ... VISTA-16 clinical study. Immediately after the ... clinical study, the Company took steps to cease patient ...
Cached Medicine Technology:JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals 2Anthera Provides Corporate Update on Recent Activities 2
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... ... 2015 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices, recently released Visio Stencils for the following product lines: ... EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual Storage ...
(Date:8/28/2015)... ... 2015 , ... Medical Solutions, one of the nation’s largest travel nurse staffing ... by Modern Healthcare and will be honored at an awards dinner in Chicago ... Best Places to Work in Healthcare program recognizes outstanding employers in the healthcare industry ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International announced that West ... day treatment and intensive family based services. , By pursuing and achieving accreditation, ... pursuit of excellence. As a nonprofit charity for more than 50 years, West ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
... long way to go before they can claim to be new generation ... their kids, according to a survey. ,The UK survey ... nearly every change and 16 percent men argue every time over the ... expert, although some men argue about the job, it might help the ...
... face different treatment options and determining which ones to ... patients decisions regarding therapy for RA and glucosamine for ... to change their treatment as long as their condition ... trial results for glucosamine. ,Recent advances in ...
... cerebral palsy hampered Anthonys ability to walk. He and his ... would be confined to a wheelchair. ,As is ... disorder, Anthony was left with few options and his family ... finding answers to effectively address his condition. ,They ...
... marketing authorization for INVEGA(TM) (paliperidone prolonged release ... treatment of schizophrenia. This once-daily medication ... the active ingredient in INVEGA - through ... ,In clinical trials, INVEGA demonstrated significant ...
... affects learning have found that boys and girls are ... ,However, they have suggested that this ... from co-educational to segregated schools, or vice-versa. ... University in NSW, said that the key to this ...
... the first success in "decrypting" an enzyme's function from its ... drug discovery. ,Led by UCSF's Brian Shoichet, ... Frank Raushel of Texas A and M, the study offers ... many of the most successful drugs work by blocking enzyme ...
Cached Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 2Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 3Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 2Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 3Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery 2
... 50 Urine Chemistry Analyzer is designed for use ... time for technicians, allowing them to be more ... It has a throughput of 50 strips per ... results, which may be downloaded to a computer ...
... collection under vacuum process makes the ... reduction. ,The Optivac® Vacuum Mixing ... of continuous improvement since its original ... a consistently high-quality, homogenous cement, with ...
... 35 years, Palacos® Bone Cement has ... standard in cemented arthroplasty. Palacos® is ... gentamicin, providing an antibiotic loaded bone ... second stage of a two-stage revision ...
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be ...
Medicine Products: